Screener
Royalty Pharma RPRX Distributions payable to non-controlling interests
Distributions payable to non-controlling interests at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept rprx:DistributionsPayableToNonControllingInterestsCurrent.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Total assets | $19,819,771 | $19,620,780 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Distributions payable to non-controlling interests | $91,280 | $72,825 |
| Accounts payable and accrued liabilities | 35,566 | 19,404 |
| Interest payable | 107,766 | 110,818 |
| Current portion of long-term debt | 380,000 | 380,000 |
| Other current liabilities | 16,316 | 53,164 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's distributions payable to non-controlling interests?
- Royalty Pharma (RPRX) reported distributions payable to non-controlling interests of $91.28M in Q2 2026.
- How has Royalty Pharma's distributions payable to non-controlling interests changed year-over-year?
- Royalty Pharma's distributions payable to non-controlling interests decreased by 7.0% year-over-year, from $98.2M to $91.28M.
- What does distributions payable to non-controlling interests mean?
- This represents the portion of earnings or cash flows owed to minority partners or non-controlling interest holders in specific royalty-generating entities. It reflects the company's obligation to distribute profits to external stakeholders based on contractual agreements.
Ask your AI about Royalty Pharma's distributions payable to non-controlling interests.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude